Cargando…

Cancer Stem Cells in Pheochromocytoma and Paraganglioma

Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors associated with high cardiovascular morbidity and variable risk of malignancy. The current therapy of choice is surgical resection. Nevertheless, PCCs/PGLs are associated with a lifelong risk of tumor persistence or recurr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scriba, Laura D., Bornstein, Stefan R., Santambrogio, Alice, Mueller, Gregor, Huebner, Angela, Hauer, Julia, Schedl, Andreas, Wielockx, Ben, Eisenhofer, Graeme, Andoniadou, Cynthia L., Steenblock, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051940/ https://www.ncbi.nlm.nih.gov/pubmed/32158431 http://dx.doi.org/10.3389/fendo.2020.00079

Ejemplares similares

Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma
por: Eisenhofer, Graeme, et al.
Publicado: (2022)

Silent pheochromocytoma and paraganglioma: Systematic review and proposed definitions for standardized terminology
por: Constantinescu, Georgiana, et al.
Publicado: (2022)

OR03-02 Identification of a Novel Stem/Progenitor Population of the Adrenal Medulla
por: Santambrogio, Alice, et al.
Publicado: (2020)

Update on Modern Management of Pheochromocytoma and Paraganglioma
por: Lenders, Jacques W. M., et al.
Publicado: (2017)

Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches
por: Costa, Marcia Helena Soares, et al.
Publicado: (2015)

Preoperative Management of Pheochromocytoma and Paraganglioma
por: Fang, Fang, et al.
Publicado: (2020)

Tumour microenvironment in pheochromocytoma and paraganglioma
por: Martinelli, Serena, et al.
Publicado: (2023)

Pheochromocytoma/paraganglioma-associated cardiomyopathy
por: Szatko, Alicja, et al.
Publicado: (2023)

Insulin and obesity transform hypothalamic-pituitary-adrenal axis stemness and function in a hyperactive state
por: Werdermann, Martin, et al.
Publicado: (2020)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma
por: Mellid, Sara, et al.
Publicado: (2023)

Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension
por: Canu, Letizia, et al.
Publicado: (2019)

Editorial: Predictive tools in pheochromocytoma and paraganglioma
por: Ceccato, Filippo, et al.
Publicado: (2023)

Adrenal Hormone Interactions and Metabolism: A Single Sample Multi-Omics Approach
por: Bechmann, Nicole, et al.
Publicado: (2021)

Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion
por: Li, Minghao, et al.
Publicado: (2021)

The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
por: Peng, Song, et al.
Publicado: (2020)

Clinical differences between small and large pheochromocytomas and paragangliomas
por: Zhao, Lin, et al.
Publicado: (2023)

Surgical strategies of complicated pheochromocytomas/paragangliomas and literature review
por: Wang, Xu, et al.
Publicado: (2023)

Glycemic Disturbances in Pheochromocytoma and Paraganglioma
por: Ronen, Joshua A, et al.
Publicado: (2019)

Predictive Factors for Catecholamine-Induced Cardiomyopathy in Patients with Pheochromocytoma and Paraganglioma
por: Wang, Yi, et al.
Publicado: (2022)

Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study
por: Ma, Xiaosen, et al.
Publicado: (2020)

Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes
por: Cui, Yunying, et al.
Publicado: (2021)

SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
por: Su, Tingwei, et al.
Publicado: (2023)

Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer
por: Jimenez, Camilo
Publicado: (2018)

Characteristics of Intraoperative Hemodynamic Instability in Postoperatively Diagnosed Pheochromocytoma and Sympathetic Paraganglioma Patients
por: Kim, Jung Hee, et al.
Publicado: (2022)

Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches
por: Kuo, Mickey J. M., et al.
Publicado: (2022)

Factors contributing to development and resolution of dysglycemia in patients with pheochromocytomas and catecholamine-secreting paragangliomas
por: Zhao, Lin, et al.
Publicado: (2023)

Lesion-based indicators predict long-term outcomes of pheochromocytoma and paraganglioma– SIZEPASS
por: Hanschell, Helena, et al.
Publicado: (2023)

OR24-4 Homeostatic and Tumourigenic Activity of SOX2+ Pituitary Stem Cells is Controlled by the LATS/YAP/TAZ Cascade
por: Lodge, Emily, et al.
Publicado: (2019)

Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma—Experiences From the GPOH-MET Registry
por: Kuhlen, Michaela, et al.
Publicado: (2022)

Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension
por: Constantinescu, Georgiana, et al.
Publicado: (2020)

Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine
por: Nölting, Svenja, et al.
Publicado: (2019)

Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background
por: Ullrich, Martin, et al.
Publicado: (2019)

Editorial: Recent Advances in Pheochromocytoma and Paraganglioma: Molecular Pathogenesis, Clinical Impacts, and Therapeutic Perspective
por: Islam, Farhadul, et al.
Publicado: (2021)

The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma
por: Wang, Yuxiong, et al.
Publicado: (2023)

Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients
por: Yamazaki, Yuto, et al.
Publicado: (2020)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

Prognostic Nomograms for Predicting Overall Survival and Cancer‐Specific Survival of Patients With Malignant Pheochromocytoma and Paraganglioma
por: Zheng, Lei, et al.
Publicado: (2021)

Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea
por: Park, Hyojung, et al.
Publicado: (2021)

Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study
por: Zhao, Lin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o86dcscuc82ac0d96146u77fl0